hrcak mascot   Srce   HID

Acta Pharmaceutica, Vol.67 No.3 Rujan 2017.

Izvorni znanstveni članak
DOI: 10.1515/acph-2017-0027

Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro, and in vivo evaluation

RAJAN RAJABALAYA ; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan BE1410, Brunei Darussalam; School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia
CHUNG YEE MUN ; School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia
JESTIN CHELLIAN ; School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia
SRIKUMAR CHAKRAVARTHI ; School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia; School of Medicine, Perdana University, Jalan MAEPS Perdana, 43400 Serdang, Selangor, Malaysia
SHEBA R. DAVID ; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan BE1410, Brunei Darussalam; School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia

Puni tekst: engleski, pdf (659 KB) str. 325-339 preuzimanja: 0* citiraj
APA
RAJABALAYA, R., MUN, C.Y., CHELLIAN, J., CHAKRAVARTHI, S., DAVID, S.R. (2017). Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro, and in vivo evaluation. Acta Pharmaceutica, 67(3). doi:10.1515/acph-2017-0027

Sažetak
The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers via the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Differential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch effectiveness, in vitro release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10–0.15 mm), tensile strength (4.62–9.98 MPa) and modulus of elasticity (20–29 MPa). There were no significant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side effects; however, studies of longer duration are required to determine the effectiveness in treating OAB.

Ključne riječi
tolterodine tartrate; transdermal; overactive bladder; matrix patches; permeation

Hrčak ID: 181339

URI
http://hrcak.srce.hr/181339

Posjeta: 0 *